Many preclinical studies have found higher PD-L1 expression on tumor cells in patients with ALK rearranged NSCLC than on other types of lung cancer cells, but clinical trials of single agent immunotherapy have not yielded significant clinical benefit. The gene discussed is ALK; the disease is non-small cell lung carcinoma.